Bulls vs Bears
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
$5.80
0.173.02%
Pre-Market: 9:02 AM EDT
Comments
Loading...
Xeris Biopharma Holdings Analyst Ratings and Price Targets | NASDAQ:XERS | Benzinga
Xeris Biopharma Holdings Inc has a consensus price target of $5.63 based on the ratings of 8 analysts. The high is $8 issued by HC Wainwright & Co. on March 7, 2025. The low is $4 issued by Piper Sandler on March 7, 2025. The 3 most-recent analyst ratings were released by Leerink Partners, Craig-Hallum, and Piper Sandler on March 7, 2025, respectively. With an average price target of $5.5 between Leerink Partners, Craig-Hallum, and Piper Sandler, there's an implied -5.17% downside for Xeris Biopharma Holdings Inc from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
Leerink Partners
Craig-Hallum
Piper Sandler
HC Wainwright & Co.
Jefferies
1calculated from analyst ratings
Analyst Ratings for Xeris Biopharma Holdings
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 03/07/2025 | Buy Now | 3.45% | Leerink Partners | Roanna Ruiz35% | $5 → $6 | Maintains | Outperform | Get Alert |
| 03/07/2025 | Buy Now | 12.07% | Craig-Hallum | Chase Knickerbocker50% | $5 → $6.5 | Maintains | Buy | Get Alert |
| 03/07/2025 | Buy Now | -31.03% | Piper Sandler | David Amsellem69% | $3 → $4 | Reiterates | Neutral → Neutral | Get Alert |
| 03/07/2025 | Buy Now | 37.94% | HC Wainwright & Co. | Oren Livnat61% | $6.6 → $8 | Reiterates | Buy → Buy | Get Alert |
| 01/29/2025 | Buy Now | 3.45% | Jefferies | Glen Santangelo50% | $4 → $6 | Reiterates | Buy → Buy | Get Alert |
| 11/11/2024 | Buy Now | 13.8% | HC Wainwright & Co. | Oren Livnat61% | $6 → $6.6 | Maintains | Buy | Get Alert |
| 11/11/2024 | Buy Now | -48.27% | Piper Sandler | David Amsellem69% | $3 → $3 | Downgrade | Overweight → Neutral | Get Alert |
| 08/15/2024 | Buy Now | 3.45% | HC Wainwright & Co. | Oren Livnat61% | $6 → $6 | Reiterates | Buy → Buy | Get Alert |
| 05/31/2024 | Buy Now | 3.45% | HC Wainwright & Co. | Oren Livnat61% | $6 → $6 | Reiterates | Buy → Buy | Get Alert |
| 05/10/2024 | Buy Now | -48.27% | Piper Sandler | David Amsellem69% | $4 → $3 | Reiterates | Overweight → Overweight | Get Alert |
| 03/28/2024 | Buy Now | -13.79% | Oppenheimer | Leland Gershell69% | → $5 | Initiates | → Outperform | Get Alert |
| 03/07/2024 | Buy Now | 3.45% | HC Wainwright & Co. | Oren Livnat61% | $5.5 → $6 | Maintains | Buy | Get Alert |
| 11/13/2023 | Buy Now | -5.17% | HC Wainwright & Co. | Oren Livnat61% | $6 → $5.5 | Maintains | Buy | Get Alert |
| 11/10/2023 | Buy Now | -31.03% | Piper Sandler | David Amsellem69% | $5 → $4 | Maintains | Overweight | Get Alert |
| 08/28/2023 | Buy Now | -22.41% | Craig-Hallum | Robin Garner26% | → $4.5 | Initiates | → Buy | Get Alert |
| 08/09/2023 | Buy Now | 3.45% | HC Wainwright & Co. | Oren Livnat61% | → $6 | Reiterates | Buy → Buy | Get Alert |
| 05/10/2023 | Buy Now | 3.45% | HC Wainwright & Co. | Oren Livnat61% | → $6 | Reiterates | Buy → Buy | Get Alert |
| 03/09/2023 | Buy Now | 3.45% | HC Wainwright & Co. | Oren Livnat61% | → $6 | Reiterates | → Buy | Get Alert |
| 01/27/2023 | Buy Now | -13.79% | SVB Leerink | Roanna Ruiz35% | $6 → $5 | Maintains | Outperform | Get Alert |
| 10/21/2022 | Buy Now | -31.03% | Jefferies | Glen Santangelo50% | → $4 | Assumes | → Buy | Get Alert |
| 04/28/2022 | Buy Now | 12.07% | Craig-Hallum | Robin Garner26% | → $6.5 | Initiates | → Buy | Get Alert |
FAQ
What is the target price for Xeris Biopharma Holdings (XERS) stock?
The latest price target for Xeris Biopharma Holdings (NASDAQ:XERS) was reported by Leerink Partners on March 7, 2025. The analyst firm set a price target for $6.00 expecting XERS to rise to within 12 months (a possible 3.45% upside). 10 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Xeris Biopharma Holdings (XERS)?
The latest analyst rating for Xeris Biopharma Holdings (NASDAQ:XERS) was provided by Leerink Partners, and Xeris Biopharma Holdings maintained their outperform rating.
When was the last upgrade for Xeris Biopharma Holdings (XERS)?
There is no last upgrade for Xeris Biopharma Holdings
When was the last downgrade for Xeris Biopharma Holdings (XERS)?
The last downgrade for Xeris Biopharma Holdings Inc happened on November 11, 2024 when Piper Sandler changed their price target from $3 to $3 for Xeris Biopharma Holdings Inc.
When is the next analyst rating going to be posted or updated for Xeris Biopharma Holdings (XERS)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Xeris Biopharma Holdings, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Xeris Biopharma Holdings was filed on March 7, 2025 so you should expect the next rating to be made available sometime around March 7, 2026.
Is the Analyst Rating Xeris Biopharma Holdings (XERS) correct?
While ratings are subjective and will change, the latest Xeris Biopharma Holdings (XERS) rating was a maintained with a price target of $5.00 to $6.00. The current price Xeris Biopharma Holdings (XERS) is trading at is $5.80, which is within the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.